Pliant Therapeutics Inc. (PLRX)
0.91
+0.01 (1.11%)
Upcoming Events
Latest Headlines
Pliant Therapeutics names siRNA research veteran as SVP
October 20, 2026 8:30 AM - StreetInsider
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
October 20, 2026 8:30 AM - StreetInsider
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
October 19, 2026 4:05 PM - StreetInsider
Form 4 PLIANT THERAPEUTICS, For: Oct 01 Filed by: Raben David
October 2, 2026 4:20 PM - SEC Filing
Form 3 PLIANT THERAPEUTICS, For: Sep 30 Filed by: Raben David
October 2, 2026 4:19 PM - SEC Filing
Pliant Therapeutics names David Raben as chief medical officer
September 30, 2026 4:10 PM - StreetInsider
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
September 30, 2026 4:10 PM - StreetInsider
Pliant Therapeutics gets FDA Fast Track for PLN-101095 in solid tumors
August 18, 2026 8:30 AM - StreetInsider
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
August 18, 2026 8:30 AM - StreetInsider
Form SCHEDULE 13G PLIANT THERAPEUTICS, Filed by: ADAR1 Capital Management, LLC
August 14, 2026 9:31 PM - SEC Filing
Form SCHEDULE 13G/A PLIANT THERAPEUTICS, Filed by: CITADEL ADVISORS LLC
August 14, 2026 4:11 PM - SEC Filing
Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 2c
August 11, 2026 5:10 PM - StreetInsider
Form 8-K PLIANT THERAPEUTICS, For: Aug 11
August 11, 2026 4:11 PM - SEC Filing
Form 10-Q PLIANT THERAPEUTICS, For: Jun 30
August 11, 2026 4:09 PM - SEC Filing
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 11, 2026 4:05 PM - StreetInsider
Full Article List
